Skip to main content

Advertisement

Figure 4 | Cancer Cell International

Figure 4

From: The effect of nilotinib plus arsenic trioxide on the proliferation and differentiation of primary leukemic cells from patients with chronic myoloid leukemia in blast crisis

Figure 4

Effects of ATO and nilotinib on cell surface antigen expression. A: The level of GPA induced by ATO and nilotinib alone or in combination (P < 0.01 vs. control). B/C: ATO and nilotinib alone or in combination elevated the expression of CD41 and CD11b (P < 0.05). Combined treatment was more potent in upregulating CD41 and CD11b levels as compared with single drug treatment. D: the expression of CD14 after drug treatment as compared with control (P > 0.05).

Back to article page